Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

13.52

Margin Of Safety %

-18

Put/Call OI Ratio

0.24

EPS Next Q Diff

-0.23

EPS Last/This Y

13.85

EPS This/Next Y

3.07

Price

9.87

Target Price

14.33

Analyst Recom

2

Performance Q

7.86

Relative Volume

0.69

Beta

1.6

Ticker: EBS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19EBS8.060.360.2826243
2024-12-20EBS8.090.350.3926162
2024-12-23EBS8.140.210.2010946
2024-12-24EBS8.30.211.1811360
2024-12-26EBS8.430.230.1611698
2024-12-27EBS8.260.230.3211887
2024-12-30EBS9.250.240.4011609
2024-12-31EBS9.550.240.2712349
2025-01-02EBS10.260.250.0013131
2025-01-03EBS10.310.240.2413864
2025-01-06EBS10.310.240.5814197
2025-01-07EBS10.290.240.1714424
2025-01-08EBS10.060.240.0414611
2025-01-09EBS10.090.240.0414611
2025-01-10EBS9.880.240.3314565
2025-01-13EBS9.40.232.2613704
2025-01-14EBS9.350.230.4513838
2025-01-15EBS9.520.240.1413979
2025-01-16EBS9.980.240.1714042
2025-01-17EBS9.890.240.0814209
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19EBS8.0616.9- -1.00
2024-12-20EBS8.0916.9- -1.00
2024-12-23EBS8.1516.9- -1.00
2024-12-24EBS8.3016.9- -1.00
2024-12-26EBS8.4216.9- -1.00
2024-12-27EBS8.2816.9- -1.00
2024-12-30EBS9.2416.9- -1.00
2024-12-31EBS9.5716.9- -1.00
2025-01-02EBS10.2416.9253.4-1.00
2025-01-03EBS10.3116.9248.0-1.00
2025-01-06EBS10.2916.9247.5-1.00
2025-01-07EBS10.2716.9247.5-1.00
2025-01-08EBS10.0916.9246.3-1.00
2025-01-09EBS10.0916.9247.7-1.00
2025-01-10EBS9.8616.9245.9-1.00
2025-01-13EBS9.4016.9243.9-1.00
2025-01-14EBS9.3416.9247.1-1.00
2025-01-15EBS9.5116.9249.0-1.00
2025-01-16EBS9.9716.9251.4-1.00
2025-01-17EBS9.8716.9247.0-1.00
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19EBS-1.803.2713.31
2024-12-20EBS-1.803.2713.31
2024-12-23EBS-1.773.3813.32
2024-12-24EBS-1.773.3813.30
2024-12-26EBS-1.803.3813.32
2024-12-27EBS-1.833.3813.32
2024-12-30EBS-1.863.3513.32
2024-12-31EBS-1.863.3513.32
2025-01-02EBS-1.773.3513.32
2025-01-03EBS-1.833.3513.32
2025-01-06EBS-1.823.1313.32
2025-01-07EBS-1.823.1313.32
2025-01-08EBS-1.833.1313.32
2025-01-09EBS-2.673.1313.15
2025-01-10EBS-2.673.1313.15
2025-01-13EBS-2.673.1213.52
2025-01-14EBS-2.673.1213.52
2025-01-15EBS-2.673.1213.52
2025-01-16EBS-2.673.1213.52
2025-01-17EBS-2.673.1213.52
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

1.37

Avg. EPS Est. Current Quarter

-0.64

Avg. EPS Est. Next Quarter

1.14

Insider Transactions

-2.67

Institutional Transactions

3.12

Beta

1.6

Average Sales Estimate Current Quarter

259

Average Sales Estimate Next Quarter

Fair Value

8.08

Quality Score

39

Growth Score

54

Sentiment Score

92

Actual DrawDown %

92.8

Max Drawdown 5-Year %

-98.9

Target Price

14.33

P/E

Forward P/E

7.69

PEG

P/S

0.48

P/B

1.05

P/Free Cash Flow

3.88

EPS

-4.1

Average EPS Est. Cur. Y​

-1

EPS Next Y. (Est.)

2.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-18.55

Relative Volume

0.69

Return on Equity vs Sector %

-60.1

Return on Equity vs Industry %

-49.7

EPS 1 7Days Diff

0.7

EPS 1 30Days Diff

0.67

EBIT Estimation

247
Emergent BioSolutions Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1600
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
stock quote shares EBS – Emergent BioSolutions Inc. Stock Price stock today
news today EBS – Emergent BioSolutions Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EBS – Emergent BioSolutions Inc. yahoo finance google finance
stock history EBS – Emergent BioSolutions Inc. invest stock market
stock prices EBS premarket after hours
ticker EBS fair value insiders trading